Efficacy of infliximab in treatment-resistant depression: A systematic review and meta-analysis

Bavaresco, Daniela V.; Uggioni, Maria Laura Rodrigues; Ferraz, Sarah Dagostin; Marques, Rudielly Moraes Machado; Simon, Carla Sasso; Dagostin, Valdemira Santina; Grande, Antônio José; Rosa, Maria Inês da

doi:10.1016/j.pbb.2019.172838

Cited by 41 publications

(23 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Infliximab showed a significant therapeutic effect—mitigated depressive symptoms—but only in patients who had increased levels of inflammatory markers [ 149 ]. Consistent with these results, a recent meta-analysis study which evaluated the antidepressant efficacy of infliximab revealed that it was effective exclusively in patients with elevated levels of inflammatory markers such TNF-α and C-reactive protein [ 150 ]. The efficacy of infliximab was also tested in patients with bipolar depression [ 151 , 152 , 153 , 154 ].…”

Section: Anti-tnf-α As a Treatment For Mood Disordersmentioning

confidence: 69%

“…However, it is important to emphasize that most of the available data regarding the antidepressant effects of selective TNF-α antagonists is derived from studies in non-psychiatric patients (i.e., patients with inflammatory-associated diseases who presented depressive symptoms). Moreover, some evidence suggests that there is no connection between anti-TNF-α therapy and improvement in mood symptoms [ 139 , 150 , 151 ]. Therefore, new randomized, placebo-controlled clinical trials are necessary for direct examination of the mood-modulating effects of TNF-α antagonists in patients with mood disorders.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Anti-TNF-α Compounds as a Treatment for Depression

Uzzan

Azab

2021

Molecules

View full text Add to dashboard Cite

Millions of people around the world suffer from psychiatric illnesses, causing unbearable burden and immense distress to patients and their families. Accumulating evidence suggests that inflammation may contribute to the pathophysiology of psychiatric disorders such as major depression and bipolar disorder. Copious studies have consistently shown that patients with mood disorders have increased levels of plasma tumor necrosis factor (TNF)-α. Given these findings, selective anti-TNF-α compounds were tested as a potential therapeutic strategy for mood disorders. This mini-review summarizes the results of studies that examined the mood-modulating effects of anti-TNF-α drugs.

show abstract

Section: Anti-tnf-α As a Treatment For Mood Disordersmentioning

confidence: 69%

Section: Resultsmentioning

confidence: 99%

Anti-TNF-α Compounds as a Treatment for Depression

Uzzan

Azab

2021

Molecules

View full text Add to dashboard Cite

show abstract

“…Little evidence reported that antidepressant treatment may decrease CRP levels [82,124], although a recent meta-analysis conducted by Wiedlocha et al (2018) [127] did not show significant effect on CRP levels using antidepressants. Based on the inflammatory theory, anti-inflammatory drugs (e.g., nonsteroidal anti-inflammatory drugs or anti-cytokine) could be useful in the treatment of depression [128][129][130][131], despite findings so far are contradictory [96,132,133].…”

Section: Discussionmentioning

confidence: 99%

C-Reactive Protein as a Biomarker for Major Depressive Disorder?

Orsolini

Pompili

Valenta

et al. 2022

IJMS

View full text Add to dashboard Cite

The etiopathogenesis of depression is not entirely understood. Several studies have investigated the role of inflammation in major depressive disorder. The present work aims to review the literature on the association between C-Reactive Protein (CRP) and depression. A systematic review was performed for the topics of ‘CRP’ and ‘depression’ using the PubMed database from inception to December 2021. Fifty-six studies were identified and included in the review. Evidence suggested the presence of dysregulation in the inflammation system in individuals with depression. In most studies, higher blood CRP levels were associated with greater symptom severity, a specific pattern of depressive symptoms, and a worse response to treatment. Moreover, about one-third of depressed patients showed a low-grade inflammatory state, suggesting the presence of a different major depressive disorder (MDD) subgroup with a distinct etiopathogenesis, clinical course, treatment response, and prognosis, which could benefit from monitoring of CRP levels and might potentially respond to anti-inflammatory treatments. This work provides robust evidence about the potential role of CRP and its blood levels in depressive disorders. These findings can be relevant to developing new therapeutic strategies and better understanding if CRP may be considered a valuable biomarker for depression.

show abstract

“…However, the off-target effects of these medications and the fact that increased inflammation occurs in only about one-third of depressed patients leaves some level of doubt regarding the specificity of findings relative to inflammation (Osimo 2019; Bavaresco 2020). Only a handful of studies have used anti-cytokine therapies in depression, and the results suggest that baseline inflammation (as reflected by CRP) is an important predictor of response, and symptoms that seem most responsive relate to anhedonia, psychomotor retardation and anxiety (Bavaresco 2020).…”

Section: Blocking Inflammation Using Cytokine Antagonistsmentioning

confidence: 99%

The immunology of stress and the impact of inflammation on the brain and behaviour

Ravi

Miller

Michopoulos³

2021

BJPsych advances

View full text Add to dashboard Cite

SUMMARY Exposure to acute versus chronic stressors and threats activates the immune system in adaptive and maladaptive manners respectively. Chronic activation arising from persistent stress exposure can contribute to an inflammatory response in the periphery and in the brain that has been implicated in stress-related psychopathology, including depression and anxiety. We review the immunology of acute and chronic stress exposure, integrate this discussion with the emerging literature linking heightened immune activation and inflammation to mood and anxiety disorders, and consider the translational implications of the immune system's role in these psychiatric conditions, with a brief overview of potential interventions.

show abstract

Efficacy of infliximab in treatment-resistant depression: A systematic review and meta-analysis

Cited by 41 publications

References 35 publications

Anti-TNF-α Compounds as a Treatment for Depression

Anti-TNF-α Compounds as a Treatment for Depression

C-Reactive Protein as a Biomarker for Major Depressive Disorder?

The immunology of stress and the impact of inflammation on the brain and behaviour

Contact Info

Product

Resources

About